Evista (raloxifene), the new designer estrogen

January 1998

You're going to hear a lot about Evista (raloxifene), the new "designer estrogen" from Lilly.

It's INITIALLY approved just to prevent osteoporosis.

But Evista and future designer estrogens will revolutionize hormone replacement therapy because they're more selective. They mimic the effects of estrogen in SOME tissues...but not others.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Evista (raloxifene), the new designer estrogen
Interactions Significant interaction between Buspar (buspirone) and erythromycin or itraconazole (Sporanox)
Interactions New drug interactions and warnings are also being reported for Posicor (mibefradil)
Cholesterol Zocor (simvastatin) is now approved to lower triglycerides
Cholesterol Baycol (cerivastatin) from Bayer
Cholesterol Switch from one statin to another
Oral Health Aphthasol (amlexanox oral paste), the first Rx drug approved for aphthous ulcers
Oral Health Colgate Total
Diabetes More frequent liver function tests for diabetics taking Rezulin (troglitazone)
Diabetes Monitor long-term blood sugar control at home
Milk thistle for hepatotoxicity
Migraine Zomig (zolmitriptan) for migraines
Migraine Migranal, a new Nasal Spray for migraines
Migraine Stadol is now a federally controlled substance (C-IV)
Two new dry powder inhalers will soon hit the market
Hematology & Oncology The first monoclonal antibody for cancer
Hair Loss Two new treatments for male-pattern hair loss
Practice Annual chart of new drugs for 1997

Evista (raloxifene), the new designer estrogen

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents